Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.

European journal of cancer (Oxford, England : 1990) - 1 Jun 2014

Stacchiotti S, Pantaleo M A, Astolfi A, Dagrada G P, Negri T, Dei Tos A P, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali P G

Abstract excerpt

BACKGROUND: Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma, marked by NR4A3 rearrangement. Herein we report on the activity of sunitinib in a series of 10 patients, strengthening what initially observed in two cases. PATIENTS AND METHODS: From July 2011, 10 patients with progressive metastatic translocated EMC have been consecutively treated with sunitinib 37.5mg/day, on a named-use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calmodulin-Binding Proteins
Share to Chondrosarcoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Receptors, Thyroid Hormone

Share to RNA-Binding Protein EWS

Share to Sunitinib

Share to TATA-Binding Protein Associated Factors

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Identifiers

PMID: 24703573
DOI: 10.1016/j.ejca.2014.03.013

Genes

EWSR1
RET
TAF15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.PMID 24703573Read ↗

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation.Semantic proximity Read ↗

Mutation of KIT In Cellular Extraskeletal Myxoid Chondrosarcoma: A Case of And Literature ReviewSemantic proximity Read ↗

Mutation of KIT in cellular extraskeletal myxoid chondrosarcoma: a case report and literature review.Semantic proximity Read ↗

Molecular oncogenesis of chondrosarcoma: impact for targeted treatmentSemantic proximity Read ↗

Long-lasting clinical benefit of sunitinib malate in the treatment of a case of heavily pre-treated metastatic liposarcoma.Semantic proximity Read ↗

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.Semantic proximity Read ↗

Phenotypic plasticity and prognostic factors in extraskeletal myxoid chondrosarcoma.Semantic proximity Read ↗

Kinome Profiling of Chondrosarcoma Reveals Src-Pathway Activity and Dasatinib as Option for TreatmentSemantic proximity Read ↗

The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor geneSemantic proximity Read ↗

NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomasSemantic proximity Read ↗

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Semantic proximity Read ↗

Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.